Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Xencor stock (XNCR)

Buy Xencor stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

About 46 hours ago


+$0.32 (+1.65%)

Xencor is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 280 staff and has a trailing 12-month revenue of around $162.2 million.

Our top picks for where to buy Xencor stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Xencor stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – XNCR. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Xencor stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Xencor stock price (NASDAQ: XNCR)

Use our graph to track the performance of XNCR stocks over time.

Xencor shares at a glance

Information last updated 2024-07-07.
Latest market close$19.71
52-week range$16.49 - $26.84
50-day moving average $21.66
200-day moving average $20.64
Wall St. target price$34.91
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.17

Is it a good time to buy Xencor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xencor price performance over time

Historical closes compared with the close of $19.71 from 2024-07-12

1 week (2024-07-05) 8.12%
1 month (2024-06-14) -4.23%
3 months (2024-04-12) -3.76%
6 months (2024-01-12) -2.91%
1 year (2023-07-14) -21.00%
2 years (2022-07-14) -35.99%
3 years (2021-07-14) 32.9
5 years (2019-07-12) 44.34

Xencor financials

Revenue TTM $162.2 million
Gross profit TTM $-34,984,000
Return on assets TTM -9.96%
Return on equity TTM -20.71%
Profit margin -82.23%
Book value $9.94
Market Capitalization $1.1 billion

TTM: trailing 12 months

Xencor share dividends

We're not expecting Xencor to pay a dividend over the next 12 months.

Xencor share price volatility

Over the last 12 months, Xencor's shares have ranged in value from as little as $16.49 up to $26.84. A popular way to gauge a stock's volatility is its "beta".

XNCR.US volatility(beta: 0.69)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.689. This would suggest that Xencor's shares are less volatile than average (for this exchange).

Xencor overview

Xencor, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression.

Frequently asked questions

What percentage of Xencor is owned by insiders or institutions?
Currently 0.937% of Xencor shares are held by insiders and 106.478% by institutions.
How many people work for Xencor?
Latest data suggests 280 work at Xencor.
When does the fiscal year end for Xencor?
Xencor's fiscal year ends in December.
Where is Xencor based?
Xencor's address is: 465 North Halstead Street, Pasadena, CA, United States, 91107
What is Xencor's ISIN number?
Xencor's international securities identification number is: US98401F1057
What is Xencor's CUSIP number?
Xencor's Committee on Uniform Securities Identification Procedures number is: 98401F105

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site